Reply to Auclin et al. Comment on “Hopkins et al. Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial. Cancers 2021, 13, 1176”

Detalles Bibliográficos
Autores principales: Hopkins, Ashley M., Kichenadasse, Ganessan, Abuhelwa, Ahmad Y., McKinnon, Ross A., Rowland, Andrew, Sorich, Michael J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Reply
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8345086/
https://www.ncbi.nlm.nih.gov/pubmed/34359664
http://dx.doi.org/10.3390/cancers13153763
Descripción
Sumario:

Ejemplares similares